Immunic, INC

Immunic, Inc. announced the appointment of Elena Ridloff to its Board of Directors and provided an update on its Phase 3 trials for vidofludimus calcium in multiple sclerosis, with top-line data expected by year-end.

Immunic, Inc. released an updated presentation on July 14, 2026, detailing its development programs, clinical trial progress, and future outlook.

Immunic, Inc. announced the resignation of Tamar Howson from its Board of Directors and Compensation Committee due to retirement, and the subsequent appointment of CEO Erik Lundgren as a Class II director.

Immunic, Inc. held its annual meeting where stockholders approved an amendment to increase shares available under its 2019 Omnibus Equity Incentive Plan and ratified the appointment of Baker Tilly as its auditor.

Immunic, Inc. presented new post-hoc analysis data from its phase 2 CALLIPER trial of vidofludimus calcium for progressive multiple sclerosis at the 2026 CMSC Annual Meeting.

Immunic, Inc. announced the appointment of Erik Lundgren as Chief Executive Officer, succeeding Daniel Vitt, Ph.D., who will remain on the Board and focus on scientific strategy.

Immunic, Inc. (IMUX) filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing clinical development for its lead multiple sclerosis drug candidate, vidofludimus calcium, while reporting increased operating expenses and a net loss.

Immunic, Inc. details its Q1 2026 financial performance and ongoing clinical development of its novel oral therapies for neurologic and gastrointestinal diseases.

Immunic, Inc. reported increased net losses and a going concern warning, alongside a Nasdaq delisting notice, despite positive clinical trial updates for its lead drug candidates.

Immunic, Inc. reported increased losses and a going concern warning, despite positive clinical trial data and recent capital raises, while also receiving a Nasdaq minimum bid price non-compliance notice.

Immunic Inc. reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern without additional funding.

Immunic Inc. reports a net loss of $24.4 million for the third quarter of 2024, while highlighting progress in its clinical development programs.

Immunic, Inc. filed an amendment to its 2025 Annual Report to provide missing corporate governance and executive compensation disclosures.

Immunic, Inc. announced a significant private placement raising $187 million, extending its operational runway while progressing its lead multiple sclerosis and celiac disease drug candidates through clinical trials and securing key intellectual property.

Immunic, Inc. files its 2024 10-K, highlighting clinical progress and financial results, while acknowledging substantial doubt about its ability to continue as a going concern without additional funding.

Immunic, Inc.'s 10-K filing outlines its capital structure, clinical development programs, and financial position, highlighting ongoing trials and recent funding.

Elena Ridloff, a Director of Immunic, Inc., received 50,740 shares of common stock on August 6, 2026.

Director Simona Skerjanec acquired 25,370 stock options in IMMUNIC, Inc. (IMUX) with an exercise price of $14.80, vesting over one year.

Richard Alan Rudick, a Director at IMMUNIC, INC., acquired 25,370 stock options on July 5, 2026, as detailed in a Form 4 filing.

Director Barclay Phillips of IMMUNIC, Inc. acquired 25,370 stock options with an exercise price of $14.80, vesting over one year.

IMMUNIC, INC. Director Joerg Neermann reported the acquisition of stock options on July 5, 2026, as part of his compensation.

IMMUNIC, INC. reports that Director Jon Congleton acquired 25,370 stock options on July 5, 2026, as part of a vesting schedule.

Immunic, Inc. announces the appointment of Erik Lundgren as CEO and seeks shareholder approval to increase its 2019 Omnibus Equity Incentive Plan by 6 million shares.

Immunic, Inc. is calling a special meeting on April 14, 2026, to seek stockholder approval for a reverse stock split to maintain its Nasdaq listing and facilitate future capital raising.

Immunic, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) pursuant to Section 14(a) of the Securities Exchange Act of 1934.

Immunic, Inc. is holding its annual stockholder meeting on June 4, 2025, to vote on the election of Class II directors, an amendment to the 2019 Omnibus Equity Incentive Plan, and the ratification of its independent auditor.

Immunic, Inc. will hold its annual stockholders meeting virtually on June 11, 2024, to vote on the election of directors, ratification of the independent accounting firm, and executive compensation.

OrbiMed Advisors LLC, OrbiMed Genesis GP LLC, and OrbiMed Capital LLC have filed a Schedule 13G, reporting beneficial ownership of Immunic, Inc. common stock.

Nantahala Capital Management, LLC, along with its managing members, has disclosed beneficial ownership of 7.47% of Immunic, Inc.'s common stock as of June 30, 2026.

Soleus Capital Master Fund, L.P. and associated entities have reported beneficial ownership of 4.9% of Immunic, Inc.'s common stock, including shares issuable upon warrant and pre-funded warrant exercise.

Several entities and an individual have filed an amendment to their Schedule 13G, confirming their beneficial ownership of Immunic, Inc. common stock.

Laurion Capital Management LP and associated individuals report beneficial ownership of 6.06% of Immunic, Inc.'s common stock, including shares issuable from warrants.

Aberdeen Group plc and abrdn Inc. have reported a combined beneficial ownership of 6.05% in IMMUNIC, Inc. common stock.